Paper Details

  1. Home
  2. Paper Details

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.

Author: FerraraF, LatagliataR, MagrinS, MeleG, MirtoS, MontilloM, PettiM C, PintoA, TedeschiA, ZagonelV

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In a study of 38 people with acute myeloid leukemia (AML) that did not respond to initial treatment or returned after treatment, 55% achieved remission after receiving a combination of fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG). Those who had a normal chromosome structure at diagnosis were more likely to respond to treatment. Side effects included low blood cell counts, mouth sores, and infections. The treatment was generally well-tolerated. Most patients who achieved remission received either a bone marrow transplant or additional chemotherapy. The study suggests that FLAG is an effective treatment option for AML that is resistant or has returned, especially for patients who are candidates for bone marrow transplantation.
Paper Details　
Original Abstract of the Article :
Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/(sici)1096-8652(199806)58:2<105::aid-ajh3>3.0.co;2-w

データ提供：米国国立医学図書館（NLM）

FLAG Regimen for Poor Risk Acute Myeloid Leukemia

Hematology, the study of blood and blood-forming tissues, is a complex and ever-evolving field. This study, published in the journal [Journal name], investigates the efficacy of a specific chemotherapy regimen, known as FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor), in treating patients with poor risk acute myeloid leukemia (AML). The researchers analyzed the outcomes of 38 patients with primary resistant or relapsing AML who underwent this treatment regimen.

A Promising Approach for Poor Risk AML

The study demonstrates that the FLAG regimen is an effective and well-tolerated treatment option for patients with refractory or recurrent AML. This finding offers valuable insights into the management of this challenging disease and underscores the importance of exploring new and innovative treatment approaches. The researchers conclude that FLAG may be particularly useful for patients who are candidates for bone marrow transplantation.

Navigating the Challenges of Leukemia Treatment

This study underscores the importance of continued research and innovation in hematology. The development of effective treatment regimens like FLAG provides hope for patients facing the challenges of leukemia. The study also emphasizes the need for personalized treatment approaches, tailored to the specific needs of each patient.

Dr. Camel's Conclusion

Just as a camel's ability to navigate the desert is crucial for its survival, developing effective treatments for challenging diseases like AML is vital for patient well-being. This study highlights the importance of exploring new treatment regimens, like FLAG, to offer hope and improve outcomes for individuals battling this disease.

Date :
  1. Date Completed 1998-06-23
  2. Date Revised 2019-08-22
Further Info :

Pubmed ID

9625576

DOI: Digital Object Identifier

10.1002/(sici)1096-8652(199806)58:2<105::aid-ajh3>3.0.co;2-w

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.